FMR LLC and Abigail Johnson reveal 9.5% CAMP4 (CAMP) ownership stake

Rhea-AI Filing Summary

FMR LLC and Abigail P. Johnson report a significant ownership stake in CAMP4 Therapeutics Corporation. As of the event date, they beneficially own 4,918,243 shares of CAMP4 common stock, representing 9.5% of the outstanding class.

FMR LLC has sole voting power over 4,916,914 shares and sole dispositive power over 4,918,243 shares, while Abigail P. Johnson is reported with sole dispositive power over the same 4,918,243 shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 01:20 PM Learn about SEC filing dates

FAQ

What percentage of CAMP4 (CAMP) shares does FMR LLC beneficially own?

FMR LLC reports beneficial ownership of 4,918,243 shares of CAMP4 Therapeutics common stock, representing 9.5% of the class. This makes FMR a significant institutional holder under Section 13 rules and triggers the requirement to file a Schedule 13G/A.

What is Abigail P. Johnson’s reported ownership in CAMP4 (CAMP)?

Abigail P. Johnson is reported as beneficially owning 4,918,243 shares of CAMP4 common stock, or 9.5% of the class. She is listed with sole dispositive power over these shares, reflecting her control relationship to FMR LLC as described in the Schedule 13G/A.

Does FMR LLC have voting power over CAMP4 (CAMP) shares?

FMR LLC reports sole voting power over 4,916,914 shares of CAMP4 common stock and no shared voting power. It also reports sole dispositive power over 4,918,243 shares, indicating control over decisions to sell those shares on behalf of its advised accounts.

Are the CAMP4 (CAMP) shares held by FMR intended to influence control of the company?

The filing states the CAMP4 shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. It also specifies they are not held in connection with any control-related transaction, except potential nomination activities under Rule 14a-11.

Who can receive dividends or sale proceeds from FMR’s CAMP4 (CAMP) holdings?

The filing notes that one or more other persons may have rights to receive dividends or sale proceeds from the CAMP4 shares. However, no single such person has an interest relating to more than 5% of the total outstanding CAMP4 common stock.

What is the event date for FMR’s CAMP4 (CAMP) Schedule 13G/A filing?

The Schedule 13G/A identifies December 31, 2025 as the date of the event requiring the filing. This date is used to determine the ownership position reported, including the 4,918,243 CAMP4 shares and the corresponding 9.5% beneficial ownership stake.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

CAMP4 THERAPEUTICS CORPORATION

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

13463J101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 13463J101

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,916,914.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,918,243.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,918,243.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.5 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 13463J101

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,918,243.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,918,243.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CAMP4 THERAPEUTICS CORPORATION
(b)	Address of issuer's principal executive offices: ONE KENDALL SQUARE,BUILDING 1400 WEST, 3RD FLOOR,CAMBRIDGE,MA,USA,02139
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 13463J101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4918243.00
(b)	Percent of class: 9.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 4918243.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CAMP4 THERAPEUTICS CORPORATION. No one other person's interest in the COMMON STOCK of CAMP4 THERAPEUTICS CORPORATION is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	02/04/2026

Abigail P. Johnson

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:	02/04/2026

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.